News | May 03, 2021
Gujarat Themis Biosyn Q4FY21 net profit lower at Rs. 5.79 Cr
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Subscribe To Our Newsletter & Stay Updated
